Daré Bioscience, Inc. (DARE) Q3 2025 Earnings Call Transcript

Daré Bioscience reported Q3 2025 with $23 million in cash, supported by $18.7 million from stock sales and $7.3 million in grants, and detailed its dual-path strategy to drive near-term revenue and long-term innovation in women's health. The company is on track to commercially launch DARE to PLAY Sildenafil Cream via 503B compounding in December 2025, expanding to all states by early 2026, and plans to introduce DARE to RESTORE vaginal probiotics in Q1 2026 and DARE to RECLAIM hormone therapy by early 2027. Concurrently, Daré continues to advance its grant-funded clinical pipeline, including the Phase III Ovaprene contraceptive, aiming to reduce dilutive capital reliance and achieve profitability through these diversified commercial and R&D initiatives.

Analysis

Daré Bioscience (DARE) reported Q3 2025 results, highlighting a strategic inflection point driven by its dual-path approach to commercialization and pipeline advancement in women's health. The company ended the quarter with approximately $23 million in cash, bolstered by $18.7 million in net proceeds from stock sales and $7.3 million in grant payments, supporting its expanded business strategy. This financial positioning enables the accelerated execution of its commercial initiatives and R&D programs.

A key near-term revenue driver is the anticipated commercial launch of DARE to PLAY Sildenafil Cream through a 503B outsourcing facility in December 2025, with full 50-state availability expected in early 2026. This product, designed for women's sexual health, represents a significant milestone as the first evidence-based topical sildenafil formulation. Additionally, Daré plans to introduce DARE to RESTORE vaginal probiotics in Q1 2026 and DARE to RECLAIM, a combination estradiol and progesterone intravaginal ring, by early 2027, leveraging the 503B pathway to accelerate patient access while pursuing traditional FDA approvals.

The company's R&D expenses decreased by 56% year-over-year to $1.2 million in Q3 2025, primarily due to increased non-dilutive funding. Grant-funded programs, including the Phase III Ovaprene contraceptive and preclinical DARE-HPV and DARE-LARC1, continue to advance, reducing reliance on dilutive capital. This balanced strategy aims to build a financially sustainable model and achieve profitability by integrating short-term commercial execution with long-term R&D investment, positioning Daré to capitalize on the underserved women's health market.

Key Decisions for Investors

• Monitor the commercial ramp-up and initial revenue generation of DARE to PLAY Sildenafil Cream in Q4 2025 and Q1 2026 as a key indicator of the company's near-term execution capabilities.
• Evaluate the market reception and regulatory pathway for DARE to RECLAIM, particularly in light of the FDA's recent positive shift in guidance regarding hormone replacement therapy.
• Assess Daré's continued success in securing non-dilutive funding for its pipeline, as this strategy is crucial for reducing shareholder dilution and supporting long-term R&D without relying heavily on equity financing, especially given current ATM limitations.